Doctoral fellow - Lab of computational cancer genomics and tumour evolution (Faculty of Medicine and Health Sciences, UGent)
Principal investigator: prof. Jimmy Van den Eynden (MD, PhD)
Doctoral fellow - Palmer lab (University of Gothenburg, Sweden)
Principal investigator: prof. Ruth Palmer (PhD)
The aim of my research is to better understand the signaling dynamics of ALK-targeted therapies in neuroblastoma and other cancer types.
ALK (Anaplastic Lymphoma Kinase) is a tyrosine kinase receptor that is a clinical target of major interest and oncogenic variants have been identified in many different tumor types, including neuroblastoma and non-small-cell lung cancer. An increasing amount of high-throughput experimental data on ALK signaling is being generated and becoming publicly available, but these data are scattered and no good methods exist to integrate different datasets.
Therefore, my PhD research has a double aim.
- The first goal is to develop a method to integrate transcriptomics and phosphoproteomics data, aiming to identify key pathways and novel drug targets in ALK-positive neuroblastoma.
- The second goal is to centralize ALK signaling data in an easy to use and interactive web platform, making ALK data more accessible, also for scientists with little or no computational background.
I obtained a Bachelor of Science in Molecular Biology in 2014 and a Master of Science in Genomics and Systems Biology in 2019, both at the University of Gothenburg. During this time, I did 2 Erasmus projects, one at the University of Barcelona in 2014 and another as part of my master thesis research at the University of Cologne in 2018. In 2020, I started a joint PhD in Jimmy van den Eynden’s lab at Ghent University and Ruth Palmer’s lab at Gothenburg University.